PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31040679-2 2019 Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system modulator, for the adjunctive treatment of major depressive disorder. Buprenorphine 96-109 COMM domain containing 3 Homo sapiens 123-126 33140519-1 2021 BACKGROUND AND AIMS: Patients with opioid use disorder (OUD) must be able to obtain prescribed buprenorphine/naloxone films (BUP/NX) and naloxone nasal spray (NNS) from a pharmacy promptly to reduce risk for a recurrence of use and subsequent morbidity and mortality. Buprenorphine 95-108 COMM domain containing 3 Homo sapiens 125-131 31028107-10 2019 These findings support the possibility that NorBUP contributes to fetal opioid dependence and NOWS following maternal buprenorphine treatment during pregnancy. Buprenorphine 118-131 COMM domain containing 3 Homo sapiens 44-50 31254971-1 2019 Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT). Buprenorphine 0-13 COMM domain containing 3 Homo sapiens 27-30 25312475-2 2015 Owing to its partial agonist properties, buprenorphine/naloxone (BUP/NX) may confer advantages over full agonist opioids for treatment of both conditions. Buprenorphine 41-54 COMM domain containing 3 Homo sapiens 65-71 30102427-1 2019 Buprenorphine/samidorphan combination (BUP/SAM) is an opioid system modulator being investigated as adjunctive treatment for major depressive disorder. Buprenorphine 0-13 COMM domain containing 3 Homo sapiens 39-42 30102427-2 2019 BUP/SAM is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist added to address the abuse and dependence potential of buprenorphine. Buprenorphine 39-52 COMM domain containing 3 Homo sapiens 0-3 30102427-2 2019 BUP/SAM is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist added to address the abuse and dependence potential of buprenorphine. Buprenorphine 233-246 COMM domain containing 3 Homo sapiens 0-3 30102427-3 2019 In this study, we assessed the effect of samidorphan on the abuse potential of buprenorphine in the BUP/SAM combination in nondependent, recreational, adult opioid users (ClinicalTrials.gov ID: NCT02413281). Buprenorphine 79-92 COMM domain containing 3 Homo sapiens 100-103 30102427-10 2019 These findings indicate that samidorphan substantially reduces the abuse potential of buprenorphine in the BUP/SAM combination. Buprenorphine 86-99 COMM domain containing 3 Homo sapiens 107-110 29257919-1 2018 BACKGROUND: Buprenorphine and naloxone (bup/nal), a combination partial mu receptor agonist and low-dose delta mu antagonist, is presently recommended and used to treat opioid-use disorder. Buprenorphine 12-25 COMM domain containing 3 Homo sapiens 40-43 27898496-2 2017 The present study aims to identify distinctive opioid use trajectories and factors associated with these patterns among participants randomized to treatment with methadone (MET) or buprenorphine + naloxone (BUP). Buprenorphine 181-194 COMM domain containing 3 Homo sapiens 207-210 26948856-1 2016 AIMS: To examine the safety and effectiveness of buprenorphine + naloxone sublingual tablets (BUP, as Suboxone( ) ) provided after administration of extended-release injectable naltrexone (XR-NTX, as Vivitrol( ) ) to reduce cocaine use in participants who met DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse. Buprenorphine 49-62 COMM domain containing 3 Homo sapiens 94-97 25935736-1 2015 OBJECTIVE: Medication assisted treatment with buprenorphine/naloxone (Bup/Nx), including prescribing and dispensing practices of general practitioners (GPs) in Malaysia and their patients" experiences with this treatment have not been systematically examined. Buprenorphine 46-59 COMM domain containing 3 Homo sapiens 70-73 24695018-2 2014 Medication-assisted treatment with buprenorphine/naloxone (BUP/NAL) has been shown to be effective up to 12 weeks. Buprenorphine 35-48 COMM domain containing 3 Homo sapiens 59-66 24999060-1 2014 BACKGROUND: Buprenorphine/naloxone (BUP/NX), an effective treatment for opioid dependence, has been implicated in hepatic toxicity. Buprenorphine 12-25 COMM domain containing 3 Homo sapiens 36-42 20672450-1 2010 BACKGROUND: This study was conducted to examine the pharmacokinetic interactions between buprenorphine/naloxone (BUP/NLX) and lopinavir/ritonavir (LPV/r) in HIV-seronegative subjects chronically maintained on BUP/NLX. Buprenorphine 89-102 COMM domain containing 3 Homo sapiens 113-120 22980449-5 2012 Data were collected for 143 patients who were induced with buprenorphine/naloxone (BUP/NLX) between June 2009 and November 2011. Buprenorphine 59-72 COMM domain containing 3 Homo sapiens 83-90 21852093-1 2012 BACKGROUND: Buprenorphine/naloxone (BUP/NX) is not licenced for use in China or Thailand and there was little clinical experience with this drug combination in these countries at the inception of HIV Prevention Trial Network (HPTN) 058, a randomized trial comparing risk reduction counselling combined with either short-term or long-term medication assisted treatment with BUP/NX to prevent HIV infection and death amongst opioid-dependent injectors. Buprenorphine 12-25 COMM domain containing 3 Homo sapiens 36-42 21852093-1 2012 BACKGROUND: Buprenorphine/naloxone (BUP/NX) is not licenced for use in China or Thailand and there was little clinical experience with this drug combination in these countries at the inception of HIV Prevention Trial Network (HPTN) 058, a randomized trial comparing risk reduction counselling combined with either short-term or long-term medication assisted treatment with BUP/NX to prevent HIV infection and death amongst opioid-dependent injectors. Buprenorphine 12-25 COMM domain containing 3 Homo sapiens 373-379 23707283-1 2013 Few studies have examined abuse of prescription opioids among individuals with chronic pain under buprenorphine/naloxone (Bup/Nx) maintenance. Buprenorphine 98-111 COMM domain containing 3 Homo sapiens 122-125 20672450-1 2010 BACKGROUND: This study was conducted to examine the pharmacokinetic interactions between buprenorphine/naloxone (BUP/NLX) and lopinavir/ritonavir (LPV/r) in HIV-seronegative subjects chronically maintained on BUP/NLX. Buprenorphine 89-102 COMM domain containing 3 Homo sapiens 209-216 19325013-1 2009 BACKGROUND: Buprenorphine (BUP) is under investigation as a medication therapy for opioid-dependent pregnant women. Buprenorphine 12-25 COMM domain containing 3 Homo sapiens 27-30 21197300-1 2009 This paper reviews the current clinical data for the role of transdermal buprenorphine (BUP TDS) in the treatment of diverse acute and chronic pain syndromes. Buprenorphine 73-86 COMM domain containing 3 Homo sapiens 88-91 17287036-1 2007 Based on prior research showing that people underestimate the influence of motivational states they are not currently experiencing, we predicted and found that heroin addicts would value an extra dose of the heroin substitute Buprenorphine more highly when they were currently craving (right before receiving BUP) than when they were currently satiated (right after receiving BUP) -- even when the extra BUP was to be received 5 days later. Buprenorphine 226-239 COMM domain containing 3 Homo sapiens 309-312 17287036-1 2007 Based on prior research showing that people underestimate the influence of motivational states they are not currently experiencing, we predicted and found that heroin addicts would value an extra dose of the heroin substitute Buprenorphine more highly when they were currently craving (right before receiving BUP) than when they were currently satiated (right after receiving BUP) -- even when the extra BUP was to be received 5 days later. Buprenorphine 226-239 COMM domain containing 3 Homo sapiens 376-379 17287036-1 2007 Based on prior research showing that people underestimate the influence of motivational states they are not currently experiencing, we predicted and found that heroin addicts would value an extra dose of the heroin substitute Buprenorphine more highly when they were currently craving (right before receiving BUP) than when they were currently satiated (right after receiving BUP) -- even when the extra BUP was to be received 5 days later. Buprenorphine 226-239 COMM domain containing 3 Homo sapiens 376-379 34218992-3 2022 OBJECTIVES: In the current study, we examined sex-based differences in psychiatric symptoms and relationships among sex, psychiatric symptoms, and opioid use outcomes in youth with OUD receiving buprenorphine/naloxone (Bup/Nal) and psychosocial treatment. Buprenorphine 195-208 COMM domain containing 3 Homo sapiens 219-222 34647379-2 2022 Although buprenorphine/naloxone (BUP/NX) is an evidence-based, first-line opioid agonist for the management of opioid use disorder, a key challenge in its prescribing lies in the fact that it can precipitate opioid withdrawal during its initial induction process. Buprenorphine 9-22 COMM domain containing 3 Homo sapiens 33-39